UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 27

Sortiert nach

2535 Clinical outcomes in chemotherapy-naïve metastatic castrationresistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate (ABI) stratified by prognosis

European journal of cancer (1990), 2015-09, Vol.51, p.S486-S487

2015

Volltextzugriff (PDF)

The Future of Systemic Therapies for Localised Prostate Cancer

Clinical oncology (Royal College of Radiologists (Great Britain)), 2013-08, Vol.25 (8), p.506-513

2013

Volltextzugriff (PDF)

Utilization of Radiation Therapy in Metastatic Castration Resistant Prostate Cancer Following the Introduction of Abiraterone into Clinical Oncology Practice

International journal of radiation oncology, biology, physics, 2012-11, Vol.84 (3), p.S361-S362

2012

Volltextzugriff (PDF)

A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel

Annals of oncology, 2016-03, Vol.27 (3), p.454-460

2016

Volltextzugriff (PDF)

693P Plasma exosome microRNA-155-3p expression in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors: Potential biomarker of response to systemic therapy

Annals of oncology, 2021-09, Vol.32, p.S708-S708

2021

Volltextzugriff (PDF)

1367P JNJ-70218902 (JNJ-902), a TMEFF2 x CD3 bispecific antibody, in prostate cancer: Initial results from a phase I dose escalation study

Annals of oncology, 2022-09, Vol.33, p.S1166

2022

Volltextzugriff (PDF)

Borealis-1: a randomized, first-line, placebo-controlled, phase II study evaluating apatorsen and chemotherapy for patients with advanced urothelial cancer

Annals of oncology, 2017-10, Vol.28 (10), p.2481-2488

2017

Volltextzugriff (PDF)

Differential expression of circulating miR375 and miR371 to detect teratoma and viable germ cell malignancy

Annals of oncology, 2019-10, Vol.30, p.v399

2019

Volltextzugriff (PDF)

983P - Differential expression of circulating miR375 and miR371 to detect teratoma and viable germ cell malignancy

Annals of oncology, 2019-10, Vol.30, p.v399-v399

2019

Volltextzugriff (PDF)

Efficacy of Enzalutamide (Enza) Following Abiraterone Acetate (Abi) in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer (Mcrpc) Patients (Pts)

Annals of oncology, 2014-09, Vol.25, p.iv272

2014

Volltextzugriff (PDF)

934P - Circulating tumour DNA (ctDNA) utility as a biomarker for metastatic urothelial carcinoma (mUC)

Annals of oncology, 2019-10, Vol.30, p.v376-v376

2019

Volltextzugriff (PDF)

Circulating tumour DNA (ctDNA) utility as a biomarker for metastatic urothelial carcinoma (mUC)

Annals of oncology, 2019-10, Vol.30, p.v376

2019

Volltextzugriff (PDF)

Plasma miR-371a-3p for detection of non-teratomatous viable germ cell tumor in testicular cancer

Annals of oncology, 2018-10, Vol.29, p.viii323-viii324

2018

Volltextzugriff (PDF)

Second-line systemic therapies for metastatic urothelial carcinoma: a population-based cohort analysis

Current oncology (Toronto), 2019-04, Vol.26 (2), p.e260-265

2019

Volltextzugriff (PDF)

Interim analysis of a phase I dose escalation trial of the antibody drug conjugate (ADC) AGS15E (ASG-15ME) in patients (Pts) with metastatic urothelial cancer (mUC)

Annals of oncology, 2016-10, Vol.27, p.vi269-vi269

2016

Volltextzugriff (PDF)

IMvigor210: updated analyses of first-line (1L) atezolizumab (atezo) in cisplatin (cis)-ineligible locally advanced/metastatic urothelial carcinoma (mUC)

Annals of oncology, 2016-10, Vol.27, p.vi270-vi270

2016

Volltextzugriff (PDF)

A phase 2 study of patupilone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: Canadian Urologic Oncology Group study P07a

Annals of oncology, 2012-01, Vol.23 (1), p.53-58

2012

Volltextzugriff (PDF)

Outcomes of peri-operative chemotherapy (PO-CT) for locally advanced penile squamous cell carcinoma (LA-PSCC): results from a multicenter analysis

Annals of oncology, 2016-10, Vol.27, p.vi291-vi291

2016

Volltextzugriff (PDF)

P024 - A randomized Phase 3 trial of Metformin in patients initiating androgen deprivation therapy as PRevention and Intervention of MEtabolic syndrome: The PRIME Study

European urology open science (Online), 2023-11, Vol.57, p.S48-S49

2023

Volltextzugriff (PDF)

A randomized Phase 3 trial of Metformin in patients initiating androgen deprivation therapy as PRevention and Intervention of MEtabolic syndrome: The PRIME Study

European urology open science (Online), 2023-11, Vol.57, p.S48-S49

2023

Volltextzugriff (PDF)

A Phase II Study of SB939 in Patients (PTS) with Castration Resistant Prostate Cancer (CRPC)

Annals of oncology, 2012-09, Vol.23, p.ix304

2012

Volltextzugriff (PDF)

Phase Ii Study of Individualized Sunitinib As First-Line Therapy for Metastatic Clear Cell Renal Cell Cancer (Mrcc)

Annals of oncology, 2014-09, Vol.25, p.iv292

2014

Volltextzugriff (PDF)

Outcomes with Cisplatin-Based First-Line Therapy for Advanced Urothelial Carcinoma (Uc) Following Previous Perioperative Cisplatin-Based Therapy

Annals of oncology, 2014-09, Vol.25, p.iv302

2014

Volltextzugriff (PDF)

Clinical outcomes of perioperative chemotherapy in patients with locally advanced penile squamous cell carcinoma: results of a multicentre analysis

Clinical genitourinary cancer, 2017

2017

Volltextzugriff (PDF)

788PEFFICACY OF ENZALUTAMIDE (ENZA) FOLLOWING ABIRATERONE ACETATE (ABI) IN CHEMOTHERAPY-NAïVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) PATIENTS (PTS)

Annals of oncology, 2014-09, Vol.25 (suppl_4), p.iv272-iv273

2014

Volltextzugriff (PDF)

1 – 25 von 27

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(27)
Mit Volltextzugriff
(27)

Publikationsform

Artikel
(27)

Sprache

Englisch
(27)

Erscheinungsjahr

n.n

Kollektion

Free E-Journal (出版社公開部分のみ）
(23)
LWW Total
(21)
IngentaConnect
(7)
MEDLINE
(5)
IngentaConnect Journals
(4)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(3)
Access via ScienceDirect (Elsevier)
(3)

2 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Annals Of Oncology
(20)
European Urology Open Science
(2)
Clinical Genitourinary Cancer
(1)
Clinical Oncology
(1)
Current Oncology
(1)
European Journal Of Cancer
(1)
International Journal Of Radiation Oncology, Biology, Physics
(1)

2 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

2535 Clinical outcomes in chemotherapy-naïve metastatic castrationresistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate (ABI) stratified by prognosis

The Future of Systemic Therapies for Localised Prostate Cancer

Utilization of Radiation Therapy in Metastatic Castration Resistant Prostate Cancer Following the Introduction of Abiraterone into Clinical Oncology Practice

A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel

693P Plasma exosome microRNA-155-3p expression in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors: Potential biomarker of response to systemic therapy

1367P JNJ-70218902 (JNJ-902), a TMEFF2 x CD3 bispecific antibody, in prostate cancer: Initial results from a phase I dose escalation study

Borealis-1: a randomized, first-line, placebo-controlled, phase II study evaluating apatorsen and chemotherapy for patients with advanced urothelial cancer

Differential expression of circulating miR375 and miR371 to detect teratoma and viable germ cell malignancy

983P - Differential expression of circulating miR375 and miR371 to detect teratoma and viable germ cell malignancy

Efficacy of Enzalutamide (Enza) Following Abiraterone Acetate (Abi) in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer (Mcrpc) Patients (Pts)

934P - Circulating tumour DNA (ctDNA) utility as a biomarker for metastatic urothelial carcinoma (mUC)

Circulating tumour DNA (ctDNA) utility as a biomarker for metastatic urothelial carcinoma (mUC)

Plasma miR-371a-3p for detection of non-teratomatous viable germ cell tumor in testicular cancer

Second-line systemic therapies for metastatic urothelial carcinoma: a population-based cohort analysis

Interim analysis of a phase I dose escalation trial of the antibody drug conjugate (ADC) AGS15E (ASG-15ME) in patients (Pts) with metastatic urothelial cancer (mUC)

IMvigor210: updated analyses of first-line (1L) atezolizumab (atezo) in cisplatin (cis)-ineligible locally advanced/metastatic urothelial carcinoma (mUC)

A phase 2 study of patupilone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: Canadian Urologic Oncology Group study P07a

Outcomes of peri-operative chemotherapy (PO-CT) for locally advanced penile squamous cell carcinoma (LA-PSCC): results from a multicenter analysis

P024 - A randomized Phase 3 trial of Metformin in patients initiating androgen deprivation therapy as PRevention and Intervention of MEtabolic syndrome: The PRIME Study

A randomized Phase 3 trial of Metformin in patients initiating androgen deprivation therapy as PRevention and Intervention of MEtabolic syndrome: The PRIME Study

A Phase II Study of SB939 in Patients (PTS) with Castration Resistant Prostate Cancer (CRPC)

Phase Ii Study of Individualized Sunitinib As First-Line Therapy for Metastatic Clear Cell Renal Cell Cancer (Mrcc)

Outcomes with Cisplatin-Based First-Line Therapy for Advanced Urothelial Carcinoma (Uc) Following Previous Perioperative Cisplatin-Based Therapy

Clinical outcomes of perioperative chemotherapy in patients with locally advanced penile squamous cell carcinoma: results of a multicentre analysis

788PEFFICACY OF ENZALUTAMIDE (ENZA) FOLLOWING ABIRATERONE ACETATE (ABI) IN CHEMOTHERAPY-NAïVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) PATIENTS (PTS)

Suchergebnisse filtern